A 26-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Multi-Center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Trial Profile

A 26-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Multi-Center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Omalizumab (Primary) ; Allergy immunotherapies
  • Indications Allergic asthma; Hypersensitivity
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Mar 2012 Results published in the Journal of Asthma.
    • 01 Feb 2010 Results published in Journal of Allergy and Clinical Immunology, Feb 2010.
    • 27 May 2008 Status changed from recruiting to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top